Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Mar;32(2):243-6.
doi: 10.6515/acs20150629b.

Regorafenib-Related Myocardial Injury during Atrial Fibrillation

Fu-Chih Hsiao  1 , Chun-Nan Yeh  2 , Pao-Hsien Chu  1
Affiliations
Case Reports

Regorafenib-Related Myocardial Injury during Atrial Fibrillation

Fu-Chih Hsiao et al. Acta Cardiol Sin. 2016 Mar.

Abstract

Multikinase inhibitors with an anti-vascular endothelial growth factor effect have been reported to increase the risk of myocardial infarction or ischemia. We have presented the case of a 72-year-old male who had a metastatic gastrointestinal stromal tumor for which he received targeted therapy and who was admitted to our hospital for recurrent episodes of myocardial injury during atrial fibrillation. Coronary angiography showed insignificant coronary artery stenosis. We also reviewed the incidence of cardiovascular events in patients receiving regorafenib, and the current understanding of the mechanism of targeted therapy-induced myocardial ischemia/infarction.

Key words: Multikinase inhibitor • Myocardial infarction • Myocardial ischemia • Vascular endothelial growth factor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Electrocardiography on presentation showed atrial fibrillation with a rapid ventricular rate, ST segment elevation in lead aVR, diffuse ST segment depression and T wave inversion. (B) Remission of the ischemic change on electrocardiography before discharge.
Figure 2
Figure 2
Coronary angiography. Insignificant stenosis on proximal left anterior descending and left circumflex arteries.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–255. - PubMed
    1. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312. - PubMed
    1. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. - PMC - PubMed
    1. Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. Crit Rev Oncol Hematol. 2014;92(3):194–207. - PubMed
    1. Wang Z, Xu J, Nie W, et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70(2):225–231. - PubMed

Publication types

LinkOut - more resources